However, a synergistic effect of the combination with gemcitabine and “p53-reactivating” compounds (CP-31398 and RITA) was found in both p53WT and p53MUT pancreatic cancer cell lines, which may have been due to a mechanism that did not involve p53 [66]. This evidence concerns the gene TP53 and familial pancreatic carcinoma.